Another recent study, combining CRISPR/Cas9 loss-of-function screens, super-resolution microscopy, and biochemistry, pinpointed MFN2 and MARCH5 as primary modes of AML resistance to BH3 mimetic drugs [127]. Here, MFN2 is linked to acute myeloid leukemia.